The goal of this clinical research study is to learn if the combination of bendamustine
hydrochloride, mitoxantrone, and rituximab can help to control follicular lymphoma.
The safety of this drug combination will also be studied.
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT00901927
Ages eligible for Study
18 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
Age >18 years at the time of signing the informed consent form.
Able to adhere to the study visit schedule and other protocol requirements.
Untreated grade 1, 2, or 3a follicular non-Hodgkin's lymphoma.
At least one measurable lesion according to the International Working Group Criteria for Response, of greater that 1.5cm.
Eastern Cooperative Oncology Group (ECOG) performance status of < 2 at study entry.
Laboratory test results within these ranges: Absolute neutrophil count >/=1.5 x 10^9/L; Platelet count >/=100 x 10^9/L; Serum creatinine </= 2.0 mg/dL; Total bilirubin </= 1.5 mg/dL; AST (SGOT) and ALT (SGPT) </= 2 x upper limit of normal (ULN) or </= 5 x ULN if hepatic metastases are present.
Disease free of prior malignancies for at least 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or breast.
Have a high risk FLIPI score, as defined by a FLIPI score >/= 3.
Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 milli-International unit (mIU)/mL within 10 to 14 days prior to study entry.
An ejection fraction of >/= 50% as documented by a cardiac function study.
Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
Pregnant or breast feeding females.
Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
Use of any prior chemotherapy for follicular lymphoma.
Known hypersensitivity to Bendamustine, mitoxantrone, or mannitol.
A history of congestive heart failure.
Any prior use of bendamustine or mitoxantrone.
Concurrent use of other anti-cancer agents or experimental treatments.
Known positive for HIV or infectious hepatitis type B or C.
Creatinine clearance less than 40 ml/min.
A known history of hepatic insufficiency (patients with a history of fulminate hepatic failure, hepatic encephalopathy, cirrhosis, and autoimmune hepatitis).
Any history of grade 3b follicular lymphoma.
All locations for NCT00901927
United States (1)
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
View full eligibility
Tris trial is registered with FDA with number: NCT00901927. The sponsor of the trial is M.D. Anderson Cancer Center and it is looking for 14 volunteers for the current phase.
Official trial title: A Phase II Study of Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Thank you for applying!
We'll contact you soon with more information.
FindMeCure is constantly improving its search. Take part in it and help millions by filling our patients' survey!